Abstract 1446
Background
Lung cancer accounts for one-quarter of all cancer deaths around the world. The identification of novel biomarkers from blood to differentiate tumors from normal tissue and to predict tumor behavior and patients’ survival is of great importance in clinical practice. We aimed to establish a nomogram with patients’ characteristics and all available hematological biomarkers for lung cancer patients.
Methods
All indexes were cataloged according to clinical significance. Principle component analysis (PCA) was used to reduce the dimensions. Each component was transformed into categorical variables based on recognized cut-off values from receiver operating characteristic (ROC) curve. Kaplan-Meier analysis with log-rank test was used to evaluate the prognostic value of each component. Multivariate analysis was used to determine the promising prognostic biomarkers. Five components were entered into a predictive nomogram. The model was subjected to bootstrap internal validation and to external validation with a separate cohort from Shandong Cancer Hospital. The predictive accuracy and discriminative ability were measured by concordance index (C index) and risk group stratification.
Results
Two hundred and fourty-eight patients were retrospectively analyzed in this study, with 134 in the Discovery Group and 114 in the Validation Group. Forty-seven indexes were sorted into 8 subgroups, and 20 principle components were extracted for further survival analysis. Via cox regression analysis, five components were significant and entered into predictive nomograms. The calibration curves for probability of 3-, and 5-year overall survival (OS) showed optimal agreement between nomogram prediction and actual observation. The new scoring system according to nomogram allowed significant distinction between survival curves within respective tumor-node-metastasis (TNM) subgroups.
Conclusions
A nomogram based on the clinical indexes was established for survival prediction of lung cancer patients, which can be used for treatment therapy selection and clinical care option. PCA makes big data analysis feasible.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3158 - Tobacco Retail Access and Tobacco Cessation Among Head and Neck Cancer (HNC) Survivors
Presenter: Lawson Eng
Session: Poster Display session 1
Resources:
Abstract
5511 - ASSERT: A Prospective, Observational Study Measuring Sodium Improvement and Outcomes in Patients Treated for Moderate to Severe Hyponatremia Secondary to Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH) in Italy (Lung Cancer Cohort)
Presenter: Rossana Berardi
Session: Poster Display session 1
Resources:
Abstract
3821 - Efficacy and safety of controlled ovarian stimulation with or without letrozole co-administration for fertility preservation: A systematic review and meta-analysis.
Presenter: Benedetta Bonardi
Session: Poster Display session 1
Resources:
Abstract
2168 - Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy
Presenter: Tineke Vandenbroucke
Session: Poster Display session 1
Resources:
Abstract
5855 - Update of the registry of young women with cancer by the International Network of Cancer, Infertility and Pregnancy
Presenter: Charlotte Maggen
Session: Poster Display session 1
Resources:
Abstract
5156 - Erectile dysfunction in patients with metastatic renal cell carcinoma
Presenter: Ilya Tsimafeyeu
Session: Poster Display session 1
Resources:
Abstract
4992 - Exercise level, interest and preferences in cancer patients.
Presenter: Alice Avancini
Session: Poster Display session 1
Resources:
Abstract
3427 - Filling the Gaps in Informed Consent for Advanced Cancer Patients considering Phase 1 Oncology Trials - an in-depth Qualitative Study of Key Stakeholders at a large United Kingdom Phase 1 unit
Presenter: Abhijit Pal
Session: Poster Display session 1
Resources:
Abstract
3537 - Breast Cancer Patients’ Quality of Life: Real World Data
Presenter: Thanos Kosmidis
Session: Poster Display session 1
Resources:
Abstract
4761 - High-sensitivity troponin as a cardiotoxicity biomarker in breast cancer treatment
Presenter: Joana Simões
Session: Poster Display session 1
Resources:
Abstract